Search filters
Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease

A Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease

18 years - 99 years
All genders
Phase 3
The main purpose of this study is to test the efficacy and safety (benefit and risks) of itolizumab, when added to corticosteroids, as treatment for aGVHD.
Learn More
A Multicenter Study to Compare T-Guard to Ruxolitinib for the Treatment of Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

A Multicenter Study to Compare T-Guard to Ruxolitinib for the Treatment of Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

18 years - 99 years
All genders
Phase 3
Interventional
Were doing this study to see how T-Guard works compared to ruxolitinib to treat aGVHD that doesnt get better with steroids. We want to know if T-Guard and ruxolitinib therapy will make aGVHD go away completely after 28 days.
Learn More

A Study to Evaluate the Efficacy and Safety of Belzutifan Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)

12 years - 99 years
All genders
Phase 2
Interventional
This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST …
Learn More
Study for the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

Study for the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

18 years - 99 years
All genders
Interventional
The purpose of this study is to continue to collect long term information on the safety of pembrolizumab or pembrolizumab-based combinations that you received or are receiving as part of the protocol you are currently enrolled in, to see how well the drug/s work and how your body reacts to …
Learn More

Preliminary investigation of beta-hydroxybutyrate supplementation in colorectal cancer prevention (BHB-CRC)

99 years or below
All genders
PURPOSE: The aim of this study is to assess the feasibility of beta-hydroxybutyrate (BHB) supplementation in individuals who are undergoing a standard-of-care colonoscopy or flexible sigmoidoscopy in order to determine whether BHB supplementation is safe and tolerable, whether BHB supplementations increases serum BHB levels, and whether BHB supplementation leads to …
Learn More
A Study to Evaluate the Safety of Trabectedin Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

A Study to Evaluate the Safety of Trabectedin Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

10 years - 99 years
All genders
Phase 1
Interventional
This study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a Positron Emission Tomography (PET) scan to help evaluate the effect of treatment.
Learn More
A Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

A Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

18 years - 99 years
All genders
Phase 2
Interventional
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-0482, MK-5890, MK-4830) in combination with pembrolizumab based therapy in patients with PD-(L)1 refractory NSCLC in a rolling-arm design
Learn More
A Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

A Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

18 years - 99 years
All genders
Phase 2
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-7684, MK-5890, MK-4830) in combination with pembrolizumab plus standard chemotherapy in treatment-naïve participants with advanced NSCLC.
Learn More
Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Na ve Metastatic Anal Cancer Patients

Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Na ve Metastatic Anal Cancer Patients

18 years - 99 years
All genders
Interventional
This trial compares the addition of nivolumab to chemotherapy (carboplatin and paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor …
Learn More
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, andAnti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected SolidTumors

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, andAnti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected SolidTumors

18 years - 99 years
All genders
To evaluate an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors. A personalized vaccine, consisting of between 4 to 20 synthetic long peptides, will be generated for each patient and shall be administered as an adjuvanted vaccine, with the adjuvant Hiltonol.
Learn More
1101 - 1110 of 1243